Technical Analysis for COGT - Cogent Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -4.40% | |
Pocket Pivot | Bullish Swing Setup | -4.40% | |
Wide Bands | Range Expansion | -4.40% | |
Oversold Stochastic | Weakness | -4.40% | |
Wide Bands | Range Expansion | 3.06% | |
Oversold Stochastic | Weakness | 3.06% | |
Earnings Movers | Other | 2.74% |
Alert | Time |
---|---|
Possible Inside Day | about 18 hours ago |
Down 5% | about 23 hours ago |
Fell Below 10 DMA | about 23 hours ago |
Gap Down Partially Closed | about 23 hours ago |
Gapped Down (Partial) | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/12/2024
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Advanced Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Advanced Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.5 |
52 Week Low | 3.67 |
Average Volume | 2,437,259 |
200-Day Moving Average | 9.06 |
50-Day Moving Average | 6.16 |
20-Day Moving Average | 7.21 |
10-Day Moving Average | 6.70 |
Average True Range | 0.62 |
RSI (14) | 49.49 |
ADX | 27.44 |
+DI | 26.84 |
-DI | 16.13 |
Chandelier Exit (Long, 3 ATRs) | 8.40 |
Chandelier Exit (Short, 3 ATRs) | 8.05 |
Upper Bollinger Bands | 8.63 |
Lower Bollinger Band | 5.78 |
Percent B (%b) | 0.34 |
BandWidth | 39.60 |
MACD Line | 0.03 |
MACD Signal Line | 0.14 |
MACD Histogram | -0.1118 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.22 | ||||
Resistance 3 (R3) | 7.24 | 7.11 | 7.14 | ||
Resistance 2 (R2) | 7.11 | 6.98 | 7.10 | 7.11 | |
Resistance 1 (R1) | 6.92 | 6.91 | 6.86 | 6.90 | 7.09 |
Pivot Point | 6.79 | 6.79 | 6.75 | 6.78 | 6.79 |
Support 1 (S1) | 6.60 | 6.66 | 6.54 | 6.58 | 6.39 |
Support 2 (S2) | 6.47 | 6.59 | 6.46 | 6.37 | |
Support 3 (S3) | 6.28 | 6.47 | 6.34 | ||
Support 4 (S4) | 6.26 |